JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on April 14, 2005; DOI: 10.1124/jpet.104.080739


0022-3565/05/3141-329-337$20.00
JPET 314:329-337, 2005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.104.080739v1
314/1/329    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Varvel, S. A.
Right arrow Articles by Lichtman, A. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Varvel, S. A.
Right arrow Articles by Lichtman, A. H.

BEHAVIORAL PHARMACOLOGY

{Delta}9-Tetrahydrocannbinol Accounts for the Antinociceptive, Hypothermic, and Cataleptic Effects of Marijuana in Mice

S. A. Varvel, D. T. Bridgen, Q. Tao, B. F. Thomas, B. R. Martin, and A. H. Lichtman

Department of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, Virginia (S.A.V., D.T.B., Q.T., B.R.M., A.H.L.); and Research Triangle Institute, Research Triangle Park, North Carolina (B.F.T.)

Although it is widely accepted that {Delta}9-tetrahydrocannabinol ({Delta}9-THC) is the primary psychoactive constituent of marijuana, questions persist as to whether other components contribute to marijuana's pharmacological activity. The present experiments assessed the cannabinoid activity of marijuana smoke exposure in mice and tested the hypothesis that {Delta}9-THC mediates these effects through a CB1 receptor mechanism of action. First, the effects of {Delta}9-THC on analgesia, hypothermia, and catalepsy were compared with those of a marijuana extract with equated {Delta}9-THC content after either i.v. administration or inhalation exposure. Second, mice were exposed to smoke of an ethanol-extracted placebo plant material or low-grade marijuana (with minimal {Delta}9-THC but similar levels of other cannabinoids) that were impregnated with varying quantities of {Delta}9-THC. To assess doses, {Delta}9-THC levels in the blood and brains of drug-exposed mice were determined following both i.v. and inhalation routes of administration. Both marijuana and {Delta}9-THC produced comparable levels of antinociception, hypothermia, and catalepsy regardless of the route of administration, and these effects were blocked by pretreatment with the CB1 antagonist SR141716 [N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl]. Importantly, the blood and brain levels of {Delta}9-THC were similar in mice exhibiting similar pharmacological effects, regardless of the presence of non-{Delta}9-THC marijuana constituents. The present experiments provide evidence that the acute cannabinoid effects of marijuana smoke exposure on analgesia, hypothermia, and catalepsy in mice result from {Delta}9-THC content acting at CB1 receptors and that the non-{Delta}9-THC constituents of marijuana (at concentrations relevant to those typically consumed) influence these effects only minimally, if at all.


Received November 15, 2004; accepted April 5, 2005.

Address correspondence to: Dr. Aron H. Lichtman, Department of Pharmacology and Toxicology, Virginia Commonwealth University, Box 980613, Richmond, VA 23298-0613. E-mail: alichtma{at}hsc.vcu.edu




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
H. R. Ross, I. Napier, and M. Connor
Inhibition of Recombinant Human T-type Calcium Channels by {Delta}9-Tetrahydrocannabinol and Cannabidiol
J. Biol. Chem., June 6, 2008; 283(23): 16124 - 16134.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
F. Niyuhire, S. A. Varvel, B. R. Martin, and A. H. Lichtman
Exposure to Marijuana Smoke Impairs Memory Retrieval in Mice
J. Pharmacol. Exp. Ther., September 1, 2007; 322(3): 1067 - 1075.
[Abstract] [Full Text] [PDF]


Home page
J. Pharmacol. Exp. Ther.Home page
S. E. O'Sullivan, M. D. Randall, and S. M. Gardiner
The in Vitro and in Vivo Cardiovascular Effects of {Delta}9-Tetrahydrocannabinol in Rats Made Hypertensive by Chronic Inhibition of Nitric-Oxide Synthase
J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 663 - 672.
[Abstract] [Full Text] [PDF]


Home page
Learn. Mem.Home page
A. F. Hoffman, M. Oz, R. Yang, A. H. Lichtman, and C. R. Lupica
Opposing actions of chronic {Delta}9-tetrahydrocannabinol and cannabinoid antagonists on hippocampal long-term potentiation
Learn. Mem., January 1, 2007; 14(1-2): 63 - 74.
[Abstract] [Full Text] [PDF]


Home page
Physiol. Rev.Home page
D. Roosterman, T. Goerge, S. W. Schneider, N. W. Bunnett, and M. Steinhoff
Neuronal control of skin function: the skin as a neuroimmunoendocrine organ.
Physiol Rev, October 1, 2006; 86(4): 1309 - 1379.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.